13 terminated. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Terminated 13 |
| Phase 2 | 2 | Terminated 2 |
Follow Embolism: new trials by email Literature Review of Embolism trials Research Report on Embolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Abelacimab, Dalteparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 417 | 2022-09-27 | 2026-04-17 |
| A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Abelacimab, Apixaban - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 1150 | 2022-05-05 | 2026-02-23 |
| Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19 Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml - COVID-19, Pulmonary Embolism, Deep Vein Thrombosis | Phase 3 | Terminated | University of Zurich | 475 | 2020-06-15 | 2022-05-25 |
| Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA), Enoxaparin - Pulmonary Embolism, Pulmonary Thromboembolisms | Phase 3 | Terminated | Rajaie Cardiovascular Medical and Research Center | 94 | 2018-12-22 | 2021-12-29 |
| Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants Apixaban, Rivaroxaban, Heparin - Renal Insufficiency | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 203 | 2016-10-19 | 2022-10-19 |
| Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging - Pulmonary Embolism | Phase 3 | Terminated | Cyclomedica Australia PTY Limited | 18 | 2012-08-01 | 2015-11-10 |
| Diclofenac for Submassive PE Diclofenac, Placebo - Pulmonary Embolism | Phase 2 / Phase 3 | Terminated | Ministry of Health, Spain | 34 | 2012-05-01 | 2017-09-06 |
| A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients dalteparin injection - Venous Thromboembolism, Pulmonary Embolism | Phase 3 | Terminated | University of Rochester | 218 | 2009-07-01 | 2015-11-24 |
| Clot Dissolving Treatment for Blood Clots in the Lungs Tenecteplase + Enoxaparin, 0.9% Saline + Enoxaparin - Pulmonary Embolism | Phase 3 | Terminated | Wake Forest University Health Sciences | 83 | 2008-05-01 | 2022-10-12 |
| Carbon Dioxide Insufflation on Cerebral Microemboli Carbon dioxide insufflation - Cardiovascular Disease, Mitral Valve Repair | Phase 2 / Phase 3 | Terminated | University Health Network, Toronto | 20 | 2008-04-01 | 2011-10-26 |
| Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery alfimeprase - Arterial Occlusive Diseases | Phase 3 | Terminated | ARCA Biopharma, Inc. | 300 | 2006-04-01 | 2008-01-15 |
| D-Dimer and IPG for Recurrent Thrombosis (DIRECT) venogram - Deep Vein Thrombosis, Pulmonary Embolism | Phase 3 | Terminated | Hamilton Health Sciences Corporation | 600 | 1998-12-01 | 2005-09-16 |
| Canadian Pulmonary Embolism Diagnosis Study (CANPEDS) Two diagnostic management strategies - Suspected Pulmonary Embolism, Deep Venous Thrombosis | Phase 3 | Terminated | Hamilton Health Sciences Corporation | 1126 | 1998-08-01 | 2006-05-03 |
Pulmonary Embolism (11) · Venous Thrombosis (6) · Venous Thromboembolism (5) · Thrombosis (3) · Ventricular Dysfunction, Right (2) · Arterial Occlusive Diseases (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Disease (1) · Gastrointestinal Neoplasms (1) · Inflammation (1) · Intermittent Claudication (1) · Renal Insufficiency (1)
Embolism and Thrombosis (13) · Vascular Diseases (13) · Cardiovascular Diseases (12) · Lung Diseases (11) · Respiratory Tract Diseases (11) · Thromboembolism (5) · Thrombosis (5) · Pathological Conditions, Signs and Symptoms (3) · Heart Diseases (2) · Pathologic Processes (2) · Ventricular Dysfunction (2) · Cognition Disorders (1) · Coronaviridae Infections (1) · Coronavirus Infections (1)
Enoxaparin (3) · Dalteparin (2) · MAA868 (2) · abelacimab (2) · apixaban (2) · Diclofenac (1) · Heart-Lung Machine (1) · Heparin (1) · Heparin, Low-Molecular-Weight (1) · Magnetic Resonance Spectroscopy (1) · Oxygenators, Membrane (1) · Rivaroxaban (1) · Sodium Chloride (1) · Technetium (1) · Tenecteplase (1)
Anthos Therapeutics, Inc. (2) · Hamilton Health Sciences Corporation (2) · ARCA Biopharma, Inc. (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Cyclomedica Australia PTY Limited (1) · Ministry of Health, Spain (1) · Rajaie Cardiovascular Medical and Research Center (1) · University Health Network, Toronto (1) · University of Rochester (1) · University of Zurich (1) · Wake Forest University Health Sciences (1)
Canada (6) · United States (6) · France (3) · Germany (3) · Italy (3) · Spain (3) · Switzerland (3) · Australia (2) · Austria (2) · China (2) · Czechia (2) · Hungary (2) · Ireland (2) · Latvia (2) · Netherlands (2)
Agnes Y Lee, MD (1) · Akash Sharma, MD (1) · Alexander G Turpie, MB (1) · Charles W. Francis, MD (1) · Clive Kearon, MD, PhD (1) · David Jimenez, MD, PhD (1) · David Leung, MD, PhD (1) · Edward M Aten, MD (1) · James Douketis, MD (1) · Jeffrey A Kline, MD (1) · Jeffrey Ginsberg, M.D. (1) · Jeffrey I Weitz, MD (1) · Jeffrey S Ginsberg, MD (1) · Mark A Crowther, MD (1)
PMID 25433511, PMID 28139259, PMID 29247809, PMID 32907635, PMID 33337539, PMID 33857326, PMID 35470214, PMID 35779558, PMID 36260302, PMID 37591523
2016 (1), 2023 (1), R01HL095109 (1)